tiprankstipranks
Trending News
More News >

Turnstone Biologics Reports Q1 Loss Amid Strategic Shift

Turnstone Biologics Reports Q1 Loss Amid Strategic Shift

Turnstone Biologics Corp. ( (TSBX) ) has released its Q1 earnings. Here is a breakdown of the information Turnstone Biologics Corp. presented to its investors.

Don’t Miss TipRanks’ Half-Year Sale

Turnstone Biologics Corp. is a biotechnology company focused on developing innovative therapies for the treatment of solid tumors, utilizing a unique approach involving tumor infiltrating lymphocytes (TILs). The company recently released its quarterly earnings report, highlighting significant strategic shifts and financial results. During the first quarter of 2025, Turnstone Biologics reported a net loss of $11.8 million, a decrease from the $19.6 million loss in the same period the previous year. The company’s cash and cash equivalents stood at $21.8 million as of March 31, 2025, down from $28.9 million at the end of 2024. The company has discontinued its clinical studies on TIDAL-01 and is exploring strategic alternatives, including potential mergers or asset sales, to enhance shareholder value. Despite these challenges, Turnstone Biologics remains committed to evaluating strategic options that could maximize shareholder value, although there is no guarantee of a favorable outcome.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1